B of A Securities analyst Susie Lee downgrades Coupang (NYSE:CPNG) from Buy to Neutral.
Anaptys Announces Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated
